2024-11-14T13:20:23-06:00 2023-12-31 812950760 SAX LLP 1040 AVENUE OF THE AMERICAS-16TH FL NEW YORK NY 10018 990 2023-01-01 871876876 THE POLG FOUNDATION INC POLG 2123158339 99 PARK AVENUE 24TH FLOOR NEW YORK NY 10016 MARCUS SIEZING TREASURER 2123158339 2024-11-14 1 0 MIKE SCHALL P02024184 2122682804 2024-11-13 2023 2024-10-15 13:58:12Z ROBERT DE LUXEMBOURG 99 PARK AVENUE 24TH FLOOR NEW YORK NY 10016 8629159 0 X POLGFOUNDATION.ORG X 2021 DE SUPPORT RESEARCH TO FIND TREATMENTS AND A CURE FOR POLG-RELATED MITOCHONDRIAL DISORDERS. 12 11 0 11 0 0 7904623 663616 0 0 0 313007 50325 6888 7954948 983511 64250 1394890 0 0 256328 0 0 0 0 470882 692801 791460 2087691 7163488 -1104180 8139856 7528235 51438 587962 8088418 6940273 X THE PURPOSES FOR WHICH THE FOUNDATION IS FORMED ARE TO ADDRESS THE UNMET MEDICAL NEEDS OF PATIENTS WITH POLG-RELATED DISORDERS WITH THE GOAL OF BEING ABLE TO MITIGATE OR CURE SUCH DISORDERS. THE FOUNDATION INTENDS TO (I) IDENTIFY HIGH-QUALITY SCIENTIFIC RESEARCH AND DISCOVERIES IN THE TREATMENT AND DIAGNOSIS OF POLG-RELATED DISORDERS, (II) PROVIDE CAPITAL TO ASSIST IN THE DEVELOPMENT OF NEW TREATMENTS AND DIAGNOSTIC TOOLS FOR SUCH DISORDERS; AND (III) FUND RESEARCH [AND] CLINICAL TRIALS, AND INVEST IN MISSION-RELATED BUSINESSES. 0 0 1892533 1394890 POLG FOUNDATION'S SUPPORTS AND ACCELERATES RESEARCH TO FIND EFFECTIVE TREATMENTS AND A CURE FOR POLG-RELATED MITOCHONDRIAL DISORDERS. 1892533 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 3 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 12 11 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 NY X X KESWICK MANAGEMENT INC 2123158339 99 PARK AVENUE 24TH FLOOR NEW YORK NY 10016 ROBERT DE LUXEMBOURG CHAIR 1.00 X X 0 0 0 JULIE DE LUXEMBOURG VICE CHAIR 7.00 X X 0 0 0 CINDY GAVIN DIRECTOR AND SECRETARY 1.00 X X 0 0 0 EILEEN KANE CORPORATE SECRETARY 1.00 X X 0 0 0 MARCUS SIEZING TREASURER 3.00 X X 0 0 0 REMY BEST DIRECTOR 1.00 X 0 0 0 ALLYSON OCEAN DIRECTOR 1.00 X 0 0 0 JENNIFER ADAMS DIRECTOR 1.00 X 0 0 0 FRANCESCO DE RUBERTIS DIRECTOR 1.00 X 0 0 0 STVEN ALTSCHULER DIRECTOR 1.00 X 0 0 0 JORG DUSCHMALE DIRECTOR 1.00 X 0 0 0 BRIAN TSENG DIRECTOR / CHIEF SCIENCE OFFICER 7.00 X 206975 0 0 206975 0 0 1 0 1 0 BRIAN TSENG PO BOX 3791 ESTES PARK CO 80517 OUTSOURCED RESEARCH 206975 MONTREUX MEDIA VENTURES SA AVENUE DES ALPES 80 B CH MONTREUX SZ 1820 MEDIA 103426 2 663616 104772 663616 234956 234956 7723699 7645648 78051 78051 78051 OTHER REVENUE 6888 6888 6888 983511 0 0 319895 X 410893 410893 983997 983997 12372 12372 77750 77750 357270 272537 84733 119477 119477 30272 28731 1541 20028 20028 837 837 POSTAGE AND SHIPPING 52201 52201 OTHER EXPENSES 12334 4669 7665 BANK CHARGES 10260 10260 2087691 1892533 195158 0 6691679 1589858 448177 223020 4764360 1000000 942997 8000 8139856 7528235 0 18036 51438 569926 51438 587962 X 7838418 6740273 250000 200000 8088418 6940273 8139856 7528235 -1104180 -43965 0 X 0 1 X 1 0 X 840696 2414743 663616 3919055 840696 2414743 663616 3919055 2851667 1067388 234956 234956 50325 6888 57213 4211224 X PART II, COLUMN (D) WE DETERMINED THE $5,489,880 EXCESS CONTRIBUTION IN 2022 SHOULD BE TREATED AS UNUSUAL GRANT AND EXCLUDED. WE MADE THE ADJUSTMENT ON COLUMN (D) OF LINE 1 AND LINE 5 ACCORDINGLY. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 OTHER INVESTMENTS 942997 F 942997 X 991747 -43965 52201 8236 983511 0 983511 2139892 52201 52201 2087691 0 2087691 PART X, LINE 2: THE FOUNDATION DOES NOT BELIEVE ITS FINANCIAL STATEMENTS INCLUDE ANY MATERIAL, UNCERTAIN TAX POSITIONS. TAX FILINGS FOR THE PERIOD ENDED DECEMBER 31, 2021, THE FOUNDATION'S INITIAL FILING, AND LATER ARE SUBJECT TO EXAMINATION BY APPLICABLE TAXING AUTHORITIES. PART XI, LINE 2D - OTHER ADJUSTMENTS: FOREIGN CURRENCY GAIN 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH GRANT RESEARCH GRANT 983997 0 0 0 0 0 0 983997 0 983997 FRANCE RESEARCH OF GENE REPLACEMENT THERAPY 320570 0 NORWAY STEM CELL BASED STUDY FOR DRUG DISCOVERY FOR POLG 246875 0 UNITED KINGDOM RESEARCH CLINICAL TRIAL REDINESS FOR POLG 165355 0 FINLAND RESEARCH TO CLARIFY MOLECULAR MECHANISMS 251197 0 0 0 0 0 0 0 0 THE JACKSON LABORATORY 600 MAIN STREET BAR HARBOR ME 04609 010211513 501 (C) (3) 46250 0 RESEARCH UNITED MITOCHONDRIAL DISEASE FOUNDATION 8085 SALTSBURG RD 201 PITTSBURGH PA 15239 251767180 501 (C) (3) 50000 0 RESEARCH THE BROAD INSTITUTE 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501 (C) (3) 312500 0 RESEARCH 2 0 0 0 0 0 0 0 0 0 BRIAN TSENG DIRECTOR / CHIEF SCIENCE OFFICER 206975 0 0 0 0 0 0 0 0 0 206975 0 0 0 X 1 104772 FMV 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 ROBERT AND JULIE DE LUXEMBOURG ARE MARRIED FORM 990, PART VI, SECTION B, LINE 11B MANAGEMENT REVIEWED A DRAFT OF THE FORM 990 WITH THE TREASURER AND SECRETARY AND PROVIDED EDITS TO THE TAX PREPARER. AFTER THIS PROCESS WAS PERFORMED, THE FORM 990 WAS SENT TO THE FULL BOARD OF DIRECTORS PRIOR TO BEING FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION HAS A WRITTEN CONFLICT OF INTEREST POLICY. THE WRITTEN POLICY REQUIRES DISCLOSURES BY ALL MEMBERS OF THE BOARD OF DIRECTORS, OFFICERS AND EMPLOYEES OF THE ORGANZATION THAT COULD GIVE RISE TO CONFLICT. THE ORGANIZATION REGULARLY MONITORS AND ENFORCES THE COMPLIANCE OF THE CONFLICT OF INTEREST POLICY. THERE WERE NO CONFLICTS OF INTEREST FOR THE TAX YEAR ENDED DECEMBER 31, 2023. FORM 990, PART VI, SECTION C, LINE 19 AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G HR CONSULTING: PROGRAM SERVICE EXPENSES 38,098. MANAGEMENT AND GENERAL EXPENSES 66,000. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 104,098. CONSULTING: PROGRAM SERVICE EXPENSES 234,439. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 234,439. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 18,733. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 18,733.